Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™

Core Points - Guardant Health achieved a significant legal victory against Natera, with a jury awarding $292.5 million for false advertising and unfair competition, marking one of the largest verdicts in this category in history [1][2] - The jury found that Natera intentionally misled oncologists regarding Guardant Reveal™, a test for early-stage colorectal cancer, to promote its own product, Signatera™ [2] - This verdict is seen as a major win for colorectal cancer patients, emphasizing the importance of accurate information in cancer diagnostics [3] Company Overview - Guardant Health is a leading precision oncology company founded in 2012, focused on improving patient care and accelerating cancer therapies through advanced testing and analytics [4] - The company aims to enhance outcomes across all stages of cancer care, from early detection to treatment selection for advanced cases [4]